Body

DALLAS, Feb. 15, 2021 -- Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year's Go Red for Women® special issue of the American Heart Association's flagship journal Circulation, published online today. Circulation editors said more than 100 manuscripts were submitted this year, the most ever in the five years in which the current editorial board has published the special issue.

A pair of UCR studies reveal that living with a romantic partner helps people feel more socially connected during COVID-19. But no other pandemic-era social dynamic carries notable benefits, the researchers found: not your kids, not kibitzing with your bestie on Facetime, and not your adorable-adoring pets.

Findings from a new Geisel-led study, published in the Journal of General Internal Medicine, reveal that there is substantial variation across different regions of the country in the intensity of fracture-associated drug (FAD) use among long-term care facility residents, and that areas with greater use of these prescription drugs experience higher hip fracture rates.

CORVALLIS, Ore. - Statistical modeling developed by Oregon State University researchers has confirmed that changes to melanoma patients' gut microbiome led them to respond to a type of treatment capable of providing long-term benefit.

Findings were published in Science.

The modeling technique invented by Andrey Morgun of the OSU College of Pharmacy and Natalia Shulzenko of Oregon State's Carlson College of Veterinary Medicine is known as transkingdom network analysis.

Certain plasma microRNAs could serve as diagnostic biomarkers in mild traumatic brain injury, a new study from the University of Eastern Finland shows. The biomarkers were discovered in an animal model and they were successfully used also to diagnose mild traumatic brain injury in a subgroup of patients. The study was published in the International Journal of Molecular Sciences.

It does not happen often. But on rare occasions, physicians make mistakes and may make a wrong diagnosis. Patients may have many diseases all at once, where it can be difficult to distinguish the symptoms of one illness from the other, or there may be a lack of symptoms.

Errors in diagnosis may lead to incorrect treatment or a lack of treatment. Therefore, everyone in the healthcare system tries to minimise errors as much as possible.

Now, researchers at the University of Copenhagen have developed an algorithm that can help with just that.

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.

The links between cardiovascular disease and cognitive impairment begin years before the appearance of the first clinical symptoms of either condition. In a study carried out at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in partnership with Santander Bank and neuroimaging experts at the Barcelonaβeta Brain Research Center (BBRC, the research center of the Fundación Pasqual Maragall), the investigators have identified a link between brain metabolism, cardiovascular risk, and atherosclerosis during middle age, years before the first appearance of symptoms.

In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice.

These findings will be presented at ASCO's virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in The Lancet.

Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer

The combination also improved progression-free survival and overall response rate

BOSTON - Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

Years of suffering and billions of euro in global health care costs, arising from osteoporosis-related bone fractures, could be eliminated using big data to target vulnerable patients, according to researchers at Lero, the Science Foundation Ireland Research Centre for Software.

Researchers from North Carolina State University used a three-model approach to trace the between-farm spread of porcine epidemic diarrhea virus (PEDV), as well as to analyze the efficacy of different control strategies in these scenarios. The approach may enable farmers to be more proactive in preventing the spread of PEDV and to optimize their efforts to control the disease.

What The Study Did: Pediatric admissions to U.S. hospitals decreased last year across an array of pediatric conditions and some may represent unmet needs in pediatric care during the COVID-19 pandemic.

Authors: Christopher M. Horvat, M.D., M.H.A., of UPMC Children's Hospital of Pittsburgh, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamanetworkopen.2020.37227)

Every year around 20 Australian children die from the incurable brain tumour, Diffuse Intrinsic Pontine Glioma (DIPG). The average age of diagnosis for DIPG is just seven years. There are no effective treatments, and almost all children die from the disease, usually within one year of diagnosis.

(BOSTON) -- Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment. In patients that have been infected by an unknown pathogen and progress to overt sepsis, every additional hour that an effective antibiotic cannot be administered significantly increases the mortality rate, so time is of utmost essence.